Thomas Hardy Selected Research

Insulin Lispro (Humalog)

1/2022	Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
1/2022	Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
12/2021	Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
1/2021	Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
1/2021	Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
11/2020	Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Hardy Research Topics

Disease

5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 11/2020
4	Weight Gain 06/2007 - 06/2006
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2003
3	Insulin Resistance 07/2012 - 01/2004
2	Injection Site Reaction 12/2021 - 01/2021
2	Bipolar Disorder (Manic Depressive Psychosis) 06/2006 - 01/2004
2	Mental Disorders (Mental Disorder) 06/2006 - 01/2004
2	Schizophrenia (Dementia Praecox) 06/2006 - 01/2004
1	Breast Neoplasms (Breast Cancer) 05/2021
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/2021
1	Small Cell Carcinoma 05/2021
1	Hyperglycemia 01/2021
1	Hypoglycemia (Reactive Hypoglycemia) 11/2020
1	Meningioma (Meningiomas) 10/2019
1	Immunoglobulin G4-Related Disease 03/2017
1	Erdheim-Chester Disease 03/2017
1	Glycosuria 01/2014
1	Neoplasms (Cancer) 10/2010
1	Body Weight (Weight, Body) 06/2007
1	Dementia (Dementias) 06/2007
1	Overweight 06/2007
1	Pain (Aches) 01/2007
1	Neuralgia (Stump Neuralgia) 01/2007
1	Weight Loss (Weight Reduction) 01/2007
1	Mania (Manias) 06/2006
1	Psychomotor Agitation (Akathisia) 06/2006
1	Psychotic Disorders (Schizoaffective Disorder) 06/2006
1	Parkinsonian Disorders (Parkinsonism) 06/2006
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2004
1	Mood Disorders (Mood Disorder) 01/2004
1	Depressive Disorder (Melancholia) 01/2004
1	Obesity 01/2004

Drug/Important Bio-Agent (IBA)

6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2006
6	Insulin Lispro (Humalog)FDA Link 01/2022 - 11/2020
3	Insulin (Novolin)FDA Link 01/2021 - 01/2021
3	Olanzapine (Zyprexa)FDA Link 06/2007 - 06/2006
3	Antipsychotic Agents (Antipsychotics)IBA 06/2007 - 11/2003
1	Estrogen ReceptorsIBA 05/2021
1	Progesterone FDA LinkGeneric 05/2021
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	Insulin Glargine (Lantus)FDA Link 11/2020
1	insulin degludecIBA 11/2020
1	Immunoglobulin G (IgG)IBA 03/2017
1	Biological ProductsIBA 10/2010
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2007
1	2,5-dichloro-4-bromophenol (B 2)IBA 06/2006
1	L 644711 (B-3(+))IBA 06/2006

Therapy/Procedure

5	Therapeutics 05/2021 - 06/2006
1	Drug Therapy (Chemotherapy) 05/2021
1	Radiotherapy 10/2019
1	Bariatric Surgery 07/2012
1	Glycemic Control 01/2007